Next Article in Journal
Triplex Real-Time PCR without DNA Extraction for the Monitoring of Meningococcal Disease
Next Article in Special Issue
RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies
Previous Article in Journal
Computer Aided Classification of Neuroblastoma Histological Images Using Scale Invariant Feature Transform with Feature Encoding
Previous Article in Special Issue
Quantitative Analysis of Seven New Prostate Cancer Biomarkers and the Potential Future of the ‘Biomarker Laboratory’
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Diagnostics 2018, 8(3), 57; https://doi.org/10.3390/diagnostics8030057

Promise and Implementation of Proteomic Prostate Cancer Biomarkers

1
Mosaiques Diagnostics GmbH, 30659 Hannover, Germany
2
Department of Urology, University Clinic of Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, Germany
*
Author to whom correspondence should be addressed.
Received: 6 August 2018 / Revised: 26 August 2018 / Accepted: 27 August 2018 / Published: 29 August 2018
(This article belongs to the Special Issue Diagnostic Biomarkers in Prostate Cancer)
Full-Text   |   PDF [1435 KB, uploaded 30 August 2018]   |  

Abstract

Prostate cancer is one of the most commonly diagnosed malignancy and the fifth leading cause of cancer mortality in men. Despite the broad use of prostate-specific antigen test that resulted in an increase in number of diagnosed cases, disease management needs to be improved. Proteomic biomarkers alone and or in combination with clinical and pathological risk calculators are expected to improve on decreasing the unnecessary biopsies, stratify low risk patients, and predict response to treatment. To this end, significant efforts have been undertaken to identify novel biomarkers that can accurately discriminate between indolent and aggressive cancer forms and indicate those men at high risk for developing prostate cancer that require immediate treatment. In the era of “big data” and “personalized medicine” proteomics-based biomarkers hold great promise to provide clinically applicable tools, as proteins regulate all biological functions, and integrate genomic information with the environmental impact. In this review article, we aim to provide a critical assessment of the current proteomics-based biomarkers for prostate cancer and their actual clinical applicability. For that purpose, a systematic review of the literature published within the last 10 years was performed using the Web of Science Database. We specifically discuss the potential and prospects of use for diagnostic, prognostic and predictive proteomics-based biomarkers, including both body fluid- and tissue-based markers. View Full-Text
Keywords: active surveillance; biomarkers; diagnosis; Prostate Cancer; proteomics active surveillance; biomarkers; diagnosis; Prostate Cancer; proteomics
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Latosinska, A.; Frantzi, M.; Merseburger, A.S.; Mischak, H. Promise and Implementation of Proteomic Prostate Cancer Biomarkers. Diagnostics 2018, 8, 57.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top